High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors

Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL

(2019) Christian Schmidl et al.   Nature Chemical Biology

From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures

(2019) Yuen-Yi Tseng et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine

(2018) Andrew J Aguirre et al.   Cancer Discovery

Genetic and transcriptional evolution alters cancer cell line drug response

(2018) Uri Ben-David et al.   NATURE

Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy

(2018) Jin-Ku Lee et al.   NATURE GENETICS

Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids

(2018) Sarah J. Hill et al.   Cancer Discovery

Drug-perturbation-based stratification of blood cancer

(2017) Sascha Dietrich et al.   JOURNAL OF CLINICAL INVESTIGATION

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

(2017) Jennifer L. Guerriero et al.   NATURE

The Drug Repurposing Hub: a next-generation drug library and information resource

(2017) Steven M Corsello et al.   NATURE MEDICINE

Functional precision cancer medicine—moving beyond pure genomics

(2017) Anthony Letai   NATURE MEDICINE

Analysis ofFusobacteriumpersistence and antibiotic response in colorectal cancer

(2017) Susan Bullman et al.   SCIENCE

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study

(2017) Berend Snijder et al.   Lancet Haematology

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

(2016) Elizabeth C. Townsend et al.   CANCER CELL

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

(2016) Mark M Stevens et al.   NATURE BIOTECHNOLOGY

Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases

(2016) Jing Ni et al.   NATURE MEDICINE

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

(2015) Joan Montero et al.   CELL

Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

(2015) Marc van de Wetering et al.   CELL

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

(2015) J Etchin et al.   LEUKEMIA

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

(2015) S. M. Guichard et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of Hepatic Energy Metabolism and Gluconeogenesis by BAD

(2014) Alfredo Giménez-Cassina et al.   Cell Metabolism

Organoid cultures for the analysis of cancer phenotypes

(2014) Norman Sachs et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response

(2013) Kristopher A. Sarosiek et al.   MOLECULAR CELL

Inconsistency in large pharmacogenomic studies

(2013) Benjamin Haibe-Kains et al.   NATURE

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

(2011) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

(2011) T. N. Chonghaile et al.   SCIENCE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: One institution's experience

(2008) Bin Wu et al.   WORLD JOURNAL OF GASTROENTEROLOGY